Despite advances in machine learning-based protein structure prediction, we are still far
from fully understanding how proteins fold into their native conformation. The conventional …

The accumulation of proteinaceous inclusions in the brain is a common feature among
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease (PD), and …

The accumulation of α-synuclein (α-syn) aggregates in specific brain regions is a hallmark of
synucleinopathies including Parkinson disease (PD). α-Syn aggregates propagate in a …

α-Synuclein (α-Syn) is the major protein component of Lewy bodies, a key pathological
feature of Parkinson's disease (PD). The manganese ion Mn 2+ has been identified as an …

Approximately half of Alzheimer's disease (AD) brains have concomitant Lewy pathology at
autopsy, suggesting that α-synuclein (α-SYN) aggregation is a regulated event in the …

Neurotransmission relies critically on the exocytotic release of neurotransmitters from small
synaptic vesicles (SVs) at the active zone. Therefore, it is essential for neurons to maintain …

Lipids represent the most abundant molecular type in the brain, with a fat content of∼ 60%
of the dry brain weight in humans. Despite this fact, little attention has been paid to …

Lewy Body Disorders (LBDs) lie within the spectrum of age-related neurodegenerative
diseases now frequently categorized as the synucleinopathies. LBDs are considered to be …

Regulation of α-synuclein (αS) fibril formation is a potent therapeutic strategy for αS-related
neurodegenerative disorders. αS, an intrinsically disordered 140-residue intraneural protein …

The aberrant aggregation of α-synuclein (αS) into amyloid fibrils is associated with a range
of highly debilitating neurodegenerative conditions, including Parkinson's disease. Although …